BANK1

BANK1 is a B cell-specific scaffold/adaptor protein that integrates signals from the B cell receptor (BCR), CD40, and Toll-like receptors (TLR7/9) to regulate B cell activation, survival, and innate immune signaling. BANK1 negatively regulates CD40-mediated Akt activation, as demonstrated by enhanced germinal center formation, IgM production, and Akt phosphorylation in BANK1-deficient mice (PMID:16546095); it also interacts with PLCγ2 in a BLK kinase-dependent manner during BCR signaling (PMID:23555801) and controls TLR9-induced IL-6 production through a p38–MNK1/2–eIF4E translational control pathway (PMID:24227780). BANK1 engages TRAF6 and MyD88 via a TIR domain, co-localizes with TLR7/9, and its two isoforms (full-length and Δ2, which lacks an IP3R-binding domain) differ in TRAF6-binding requirements and K63-linked polyubiquitination, producing distinct downstream signaling outputs including differential IL-8 production (PMID:31243359, PMID:18204447). Genetic variants in BANK1 are causally linked to systemic lupus erythematosus (SLE), with risk alleles impairing BCR/CD40-dependent Akt suppression and FOXO1 regulation, and rare coding variants disrupting IRF5 and type-I interferon control (PMID:27816669, PMID:31101814).

1. 2006 High

   The central question of BANK1's physiological role was answered by showing it negatively regulates CD40-mediated Akt activation in B cells, restraining germinal center formation and B cell survival — establishing BANK1 as a signaling brake rather than an activator.

   Evidence BANK1 knockout mice with epistasis analysis using dominant-negative Akt in primary B cells

   PMID:16546095

   Open questions at the time

   • Direct biochemical mechanism by which BANK1 suppresses Akt phosphorylation was not identified
   • Relationship to BCR-proximal signaling molecules not defined
2. 2008 Medium

   Discovery of two BANK1 isoforms (full-length with an IP3R-binding domain and Δ2 lacking it) revealed how alternative splicing at a disease-associated branch-point SNP diversifies BANK1 signaling outputs, connecting isoform expression to SLE susceptibility.

   Evidence cDNA isoform cloning, functional SNP analysis, and linkage disequilibrium mapping in human B cells

   PMID:18204447

   Open questions at the time

   • IP3R-binding domain function not biochemically reconstituted
   • Relative expression levels and ratio of isoforms across B cell subsets not established
3. 2013 High

   Two studies clarified BANK1's dual engagement with BCR and TLR pathways: BANK1 interacts with PLCγ2 in a BLK-dependent manner upon BCR stimulation, and independently controls TLR9-induced IL-6 secretion via a p38–MNK1/2–eIF4E translational axis, establishing BANK1 as a node linking adaptive and innate immune receptor signaling.

   Evidence Yeast two-hybrid, co-immunoprecipitation and mutagenesis for PLCγ2 interaction; Bank1 KO B cells with CpG stimulation, phospho-signaling, and mRNA stability assays for TLR9 pathway

   PMID:23555801 PMID:24227780

   Open questions at the time

   • Whether PLCγ2 interaction and TLR9-p38 pathway converge on shared downstream effectors is unknown
   • PLCγ2 interaction demonstrated in single lab without independent replication
4. 2016 Medium

   Translating the KO phenotype to human disease, SLE-risk BANK1 variants were shown to reduce proximal BCR signaling and blunt Akt activation in human B cells, with increased basal FOXO1 and expansion of memory B cells, mechanistically linking BANK1 function to lupus pathogenesis.

   Evidence Targeted phospho-proteomics in engineered human B cell lines and primary B cells from genotyped donors

   PMID:27816669

   Open questions at the time

   • How reduced Akt activation paradoxically promotes autoimmunity rather than immunodeficiency is not mechanistically resolved
   • FOXO1-dependent gene program downstream of BANK1 variants not comprehensively defined
5. 2019 High

   The molecular basis of BANK1's innate immune function was resolved: its TIR domain mediates interaction with TRAF6 and MyD88, with isoform-specific differences in TRAF6 binding and K63-linked polyubiquitination controlling differential IL-8 and type-I IFN outputs, while rare BANK1 variants in SLE patients impair IRF5 suppression.

   Evidence Co-IP, point mutagenesis, decoy peptides, confocal colocalization in mouse splenic B cells for TIR domain study; functional assays in human B cell lines with engineered rare variants and lupus-prone mouse models for IRF5/IFN study

   PMID:31101814 PMID:31243359

   Open questions at the time

   • Structural basis of TIR domain interaction with TRAF6/MyD88 not determined
   • Whether BANK1 isoform ratio shifts during disease progression is unknown
   • How BANK1 integrates CD40, BCR, and TLR signals simultaneously in the same cell remains unresolved

• It remains unknown how BANK1 mechanistically suppresses Akt phosphorylation downstream of CD40, whether its scaffold function involves direct enzymatic recruitment or allosteric effects, and how the full-length and Δ2 isoforms partition across B cell developmental stages to shape humoral immune responses.
• Direct Akt-suppressive mechanism not identified
• No structural model of BANK1 or its domain complexes exists
• Isoform-specific functions during in vivo immune responses not dissected